In addition, use of an anti-TGF-β1 neutralizing antibody to block TGF-β/Smad3 signaling protects mice from obesity, diabetes, and hepatic steatosis (Tan et al., 2011; Yadav et al., 2011). Here, TGFB1 is linked to obesity disorder.